How should hypertension be managed in chronic kidney disease?

Management of Hypertension in Chronic Kidney Disease

For patients with hypertension and CKD, target a blood pressure of <130/80 mm Hg using standardized office measurement, and initiate treatment with an ACE inhibitor (or ARB if ACE inhibitor not tolerated) as first-line therapy in those with proteinuria (≥300 mg/d or albumin-to-creatinine ratio ≥30 mg/mmol). 1, 2, 3

Blood Pressure Targets

The most recent and highest-quality evidence supports more intensive BP control than older guidelines:

• Target BP: <130/80 mm Hg for all adults with hypertension and CKD 1, 2, 4, 5, 3
• This target is based on standardized office BP measurement, not routine casual office readings 3, 6
• The KDIGO 2021 guideline goes further, recommending a target SBP <120 mm Hg when using standardized measurement techniques, though this is a conditional recommendation requiring shared decision-making 3, 6

Critical caveat: Older Canadian guidelines from 2011-2015 recommended <130/80 mm Hg for nondiabetic CKD 7 or even <140/90 mm Hg 8, but these have been superseded by more recent evidence showing cardiovascular and mortality benefits with lower targets.

Measurement Technique Matters

Use standardized office BP measurement - this means:

• Patient relaxed, sitting with back supported and feet on floor for >5 minutes
• Avoid routine/casual office measurements which are unreliable 3, 6
• Consider ambulatory BP monitoring (ABPM) or home BP monitoring to supplement office readings 3

The discrepancy between routine and standardized BP can be substantial - applying intensive targets to routine measurements risks overtreatment and adverse events 6.

First-Line Pharmacotherapy

For Proteinuric CKD (Albuminuria ≥300 mg/d or ACR ≥30 mg/mmol):

Start with ACE inhibitor (Grade A evidence) 7, 1, 2, 3

• This applies to both diabetic and nondiabetic CKD with significant proteinuria
• Use ARB if ACE inhibitor not tolerated (Grade B evidence) 7, 1, 2, 3
• Use the highest approved tolerated dose - the proven benefits were achieved with these doses in trials 3

For Non-Proteinuric CKD:

ACE inhibitors or ARBs may be reasonable but are not as strongly indicated 3. Consider other first-line agents including:

• Long-acting dihydropyridine calcium channel blockers
• Thiazide or thiazide-like diuretics (for stages 1-3 CKD)
• Loop diuretics (for stage 4-5 CKD or volume overload) 7

Combination Therapy

Most patients will require 2-3 antihypertensive agents to reach target BP 7:

1. Second-line agents to add to ACE inhibitor/ARB:

   • Thiazide/thiazide-like diuretics (for eGFR ≥30 mL/min) 7
   • Loop diuretics (for eGFR <30 mL/min or volume overload) 7
   • Long-acting dihydropyridine calcium channel blockers 7

2. For resistant hypertension:

   • Add mineralocorticoid receptor antagonist (spironolactone), but monitor closely for hyperkalemia, especially with eGFR <45 mL/min 3

Never combine ACE inhibitor + ARB - this is explicitly not recommended due to increased risk of adverse events without additional benefit 7, 3

Monitoring After Initiation

Check within 2-4 weeks of starting or increasing dose 3:

• Serum creatinine (acceptable if rises <30% from baseline)
• Serum potassium
• Blood pressure

Continue ACE inhibitor/ARB unless:

• Creatinine rises >30% within 4 weeks 3
• Symptomatic hypotension occurs
• Uncontrolled hyperkalemia despite management 3

Managing Hyperkalemia

Do not automatically stop ACE inhibitor/ARB for hyperkalemia - instead 3:

• Implement dietary potassium restriction
• Consider potassium binders
• Adjust diuretic therapy
• Only reduce dose or discontinue if hyperkalemia remains uncontrolled despite these measures

This approach preserves the cardiovascular and renal protective benefits of renin-angiotensin system blockade.

Special Populations

Renovascular Disease:

• Use caution with ACE inhibitors/ARBs in bilateral renal artery stenosis or stenosis in a solitary kidney due to acute renal failure risk 7
• Consider revascularization only for uncontrolled hypertension on ≥3 drugs, declining renal function, or recurrent flash pulmonary edema 7

Kidney Transplant Recipients:

• Target BP <130/80 mm Hg 4
• Use dihydropyridine calcium channel blocker or ARB as first-line (improved GFR and kidney survival) 4

Emerging Therapies

Recent evidence supports considering:

• SGLT-2 inhibitors for cardio-renal protection (modest BP lowering effect) 9, 10
• Non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone) for patients at high risk 9, 10

These provide disease-modifying benefits beyond BP reduction alone.